Investigational drug · Phase 3
ATB-1011
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Essential Hypertension, Diabetes Mellitus, Type 2.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "ATB-1011"
First trial start
2022
Nov 16, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ATB-1011", any sponsor or status.
Conditions studied
As listed on its trial records.
- Essential Hypertension
- Diabetes Mellitus, Type 2
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "ATB-1011" as an intervention, largest first.
- Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II DiabetesPivotal-lookingCompleted
AutotelicbioIndustry
NCT05573477 · 255 participants · Start Nov 16, 2022 · Primary completion Aug 31, 2025
Drug: ATB-1011; ATB-1012 and 4 more · For: Essential Hypertension; Diabetes Mellitus, Type 2
Sites: Seongnam-si, South Korea
AutotelicbioIndustry
NCT04856969 · 38 participants · Start Mar 30, 2021 · Primary completion May 4, 2021
Drug: Olmesartan; Dapagliflozin · For: Healthy Adult Volunteers
Sites: Seoul, South Korea
- A Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian ParticipantsNot yet recruiting
AutotelicbioIndustry
NCT07590466 · 36 participants (planned) · Start May 18, 2026 · Primary completion Jul 31, 2026
Drug: ATB-U101; ATB-1011 and 3 more · For: Diabete Type 2; Hypertension
AutotelicbioIndustry
NCT05017987 · 36 participants · Start Jun 19, 2021 · Primary completion Jul 12, 2021
Drug: ATB-101, ATB-1011, ATB-1012 · For: Healthy Adult Volunteers
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Essential Hypertension
- DWC202314Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- DWC202314PPhase 32 trials
Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension
- Experimental: SacubitrilPhase 32 trials
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Essential Hypertension
- AD-227APhase 31 trial
Addpharma Inc. · Essential Hypertension
- AD-227BPhase 31 trial
Addpharma Inc. · Essential Hypertension
- AD-227CPhase 31 trial
Addpharma Inc. · Essential Hypertension
- ATB-1012Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
- ATB-1013Phase 31 trial
Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.